Envestnet Asset Management Inc Outlook Therapeutics, Inc. Transaction History

Envestnet Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.2 - $1.78 $5,191 - $46,201	25,956 Added 53.49%	74,482 $16,000
Q2 2023 Aug 04, 2023	SELL	$1.02 - $1.89 $2,201 - $4,078	-2,158 Reduced 4.26%	48,526 $84,000
Q1 2023 May 11, 2023	BUY	$1.0 - $1.35 $23,094 - $31,176	23,094 Added 83.7%	50,684 $55,000
Q4 2022 Feb 07, 2023	SELL	$0.87 - $1.33 $845 - $1,292	-972 Reduced 3.4%	27,590 $29,000
Q3 2022 Nov 10, 2022	BUY	$1.02 - $1.26 $3,925 - $4,849	3,849 Added 15.57%	28,562 $35,000
Q2 2022 Aug 03, 2022	BUY	$0.91 - $2.01 $154 - $341	170 Added 0.69%	24,713 $25,000
Q1 2022 May 04, 2022	SELL	$1.22 - $2.03 $14,539 - $24,193	-11,918 Reduced 32.69%	24,543 $44,000
Q4 2021 Feb 04, 2022	BUY	$1.27 - $2.23 $46,305 - $81,308	36,461 New	36,461 $50,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.